ArticleAntimicrobial agents and chemotherapy1994
Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis.
Article in Antimicrobial agents and chemotherapy, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 128 citations in OpenAlex.
- Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.Hepatology international · 2016Trial
- Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.The Journal of infectious diseases · 2009Trial
- Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence.Digestive diseases and sciences · 2002Trial
- Mosapride Stabilizes Intestinal Microbiota to Reduce Bacterial Translocation and Endotoxemia in CClDigestive diseases and sciences · 2017Article
- Could Adherence to Quality of Care Indicators for Hospitalized Patients With Cirrhosis-Related Ascites Improve Clinical Outcomes?The American journal of gastroenterology · 2016Article
- Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding.World journal of gastroenterology · 2014Review
- Update on the management of cirrhosis - focus on cost-effective preventative strategies.ClinicoEconomics and outcomes research : CEOR · 2013Article
- Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study.Gut and liver · 2009Article
- Spontaneous bacterial peritonitis: a review of treatment options.P & T : a peer-reviewed journal for formulary management · 2009Article
- Spontaneous bacterial peritonitis.World journal of gastroenterology · 2009Review
- [Collateral damage of cephalosporins and quinolones and possibilities for control].Medizinische Klinik (Munich, Germany : 1983) · 2009Review
- Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension.Digestive diseases and sciences · 2003Article
- New developments and concepts in antimicrobial therapy for intra-abdominal infections.Current gastroenterology reports · 2000Review
- Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae.Journal of clinical microbiology · 1999Article
- Changes in nature and antibiotic resistance of bacteria causing peritonitis in cirrhotic patients over a 20 year period.Journal of clinical pathology · 1998Article
- Primary and secondary peritonitis: an update.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 1998Review
- Review
- A nosocomial outbreak due to Enterobacter cloacae strains with the E. hormaechei genotype in patients treated with fluoroquinolones.Journal of clinical microbiology · 1997Article
- The population dynamics of antimicrobial chemotherapy.Antimicrobial agents and chemotherapy · 1997Article
- Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.Journal of clinical microbiology · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We carried out quantitative culturing of stools from 31 hospitalized alcoholic patients with cirrhosis and ascites, before treatment with 400 mg of norfloxacin per day, weekly for the first month, and then every 2 weeks thereafter for 15 to 229 days (median, 54 days). Members of the family Enterobacteriaceae virtually disappeared from the stools (< 10(2)/g), but treatment had little effect on enterococci. No selection of resistant organisms occurred in 15 patients, but the remaining 16 patients developed fecal organisms resistant to fluoroquinolones between days 14 and 43 of treatment (median, 25 days). Staphylococcus aureus was isolated four times, coagulase-negative Staphylococcus spp. were isolated six times, Citrobacter freundii was isolated four times, Enterobacter cloacae was isolated three times, Klebsiella oxytoca was isolated twice, Proteus rettgeri was isolated once, and untypeable streptococci were isolated six times. Some isolates persisted, while others were transient (one to seven consecutively positive cultures). The MICs of four quinolones (nalidixic acid, norfloxacin, ofloxacin, and ciprofloxacin) were determined by use of experimental microwell strips (ATB CMI; Biomerieux S.A.). All the strains isolated before treatment were susceptible to the four quinolones, with low MICs, whereas those isolated during norfloxacin treatment were highly resistant. Long-term norfloxacin administration thus carries a risk of disturbing the bacterial ecology in these patients, suggesting that digestive decontamination should no longer be prescribed routinely to cirrhotic patients with ascites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.